A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease

@article{Dyck2007A2R,
  title={A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease},
  author={C. V. van Dyck and P. Tariot and B. Meyers and E. Malca Resnick},
  journal={Alzheimer Disease \& Associated Disorders},
  year={2007},
  volume={21},
  pages={136-143}
}
This study examined the efficacy and safety of memantine monotherapy in patients with moderate-to-severe Alzheimer disease (AD). Patients not receiving a cholinesterase inhibitor (N=350) were randomized to receive memantine (20 mg/d) or placebo during this 24-week, double-blind, placebo-controlled trial. Prospectively defined analyses failed to demonstrate a statistically significant benefit of memantine treatment compared with placebo on the Severe Impairment Battery (SIB) at week 24 end point… Expand
Update on the use of memantine in Alzheimer’s disease
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date
  • R. Bullock
  • Medicine
  • Alzheimer disease and associated disorders
  • 2006
Memantine in moderate-to-severe Alzheimer's disease.
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
  • S. Lipton
  • Medicine
  • Current Alzheimer research
  • 2005
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease
The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease
Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
...
1
2
3
...